4.6 Article

The Effect of ABO Blood Incompatibility on Corneal Transplant Failure in Conditions with Low-risk of Graft Rejection

Journal

AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 147, Issue 3, Pages 432-438

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2008.09.021

Keywords

-

Categories

Funding

  1. NATIONAL EYE INSTITUTE, NATIONAL INSTITUTES of Health, Bethesda, Maryland and Department of Health and Human Services [EY12728, EY12358]
  2. Eye Bank Association of America, Washington, DC
  3. Bausch & Lomb Inc, Rochester, New York
  4. Tissue Banks International, Baltimore, Maryland
  5. Vision Share Inc, Apex, North Carolina
  6. San Diego Eye Bank, San Diego, California
  7. The Cornea Society, Fairfax, Virginia
  8. Karena Products Inc, Denville, New Jersey
  9. ViroMed Laboratories Inc, Minnetonka, Minnesota
  10. Midwest Eye Banks (Michigan Eye Bank, Illinois Eye Bank), Ann Arbor, Michigan
  11. Konan Medical Corp, Torrance, California

Ask authors/readers for more resources

PURPOSE: To determine whether corneal graft survival over a 5-year follow-up period was affected by ABO blood type compatibility in participants in the Cornea Donor Study undergoing corneal transplantation principally for Fuchs dystrophy or pseudophakic corneal edema, conditions at low-risk for graft rejection. DESIGN: Multi-center prospective, double-masked, clinical trial. METHODS: ABO blood group compatibility was determined for 1,002 donors and recipients. During a 5,year follow-up period, episodes of graft rejection were documented, and graft failures were classified as to whether or not they were attributable to immunologic rejection. Endothelial cell density was determined by a central reading center for a subset of subjects. RESULTS: ABO donor-recipient incompatibility was not associated with graft failure attributable to any cause including graft failure because of rejection, or with the occurrence of a rejection episode. The 5-year cumulative incidence of graft failure attributable to rejection was 32 (6%) for recipients with ABO recipient-donor compatibility and 12 (4%) for those with ABO incompatibility (hazard ratio, 0.65; 95% confidence interval, 0.33 to 1.25; P =.20). The 5-year incidence for a definite rejection episode, irrespective of whether graft failure ultimately occurred, was 64 (12%) for ABO compatible compared with 25 (8%) for ABO incompatible cases (P = .09). Among clear grafts at 5 years, percent loss of endothelial cells was similar in ABO compatible and incompatible cases. CONCLUSIONS: In patients undergoing penetrating keratoplasty for Fuchs dystrophy or pseudophakic corneal edema, ABO matching is not indicated since ABO incompatibility does not increase the risk of transplant failure attributable to graft rejection. (Am J Ophthalmol 2009;147:432-438. (C) 2009 by Elsevier Inc. All rights reserved.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available